Enanta Pharmaceuticals (ENTA) Change in Receivables (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Change in Receivables came in at -$684000.0 in Q1 2026, up 26.13% YoY from -$542280.8 in Q1 2025, and down 142.46% on a QoQ basis from $1.6 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Change in Receivables (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Change in Receivables data on file, last reported at -$684000.0 in Q1 2026.
- Quarterly Change in Receivables rose 26.13% year-over-year to -$684000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (up 205.5% YoY) and the FY2025 annual result came in at $236000.0, up 111.99% from the prior year.
- Change in Receivables fell to -$684000.0 in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $2.3 million in Q4 2022 to a low of -$10.3 million in Q3 2023.
- A 5-year average of -$1.2 million and a median of -$417000.0 in 2024 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2023 — Change in Receivables slumped 1325.03% — and 2024, when it surged 343.08%.
- Tracing ENTA's Change in Receivables over 5 years: stood at $2.3 million in 2022, then tumbled by 119.45% to -$441000.0 in 2023, then jumped by 343.08% to $1.1 million in 2024, then jumped by 50.28% to $1.6 million in 2025, then slumped by 142.46% to -$684000.0 in 2026.
- The last three Change in Receivables figures came in at -$684000.0 (Q1 2026), $1.6 million (Q4 2025), and -$1.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | -1.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.28 Mn |
| Jun 30, 2026 | -1.28 Mn |
| Mar 31, 2026 | -684,000.00 |
| Mar 31, 2026 | -684,000.00 |
| Dec 31, 2025 | 1.61 Mn |
| Dec 31, 2025 | 1.61 Mn |
| Sep 30, 2025 | -1.45 Mn |
| Sep 30, 2025 | -1.45 Mn |
| Jun 30, 2025 | 1.54 Mn |
| Jun 30, 2025 | 1.54 Mn |
| Mar 31, 2025 | -926,000.00 |
| Mar 31, 2025 | -926,000.00 |
| Dec 31, 2024 | 1.07 Mn |
| Dec 31, 2024 | 1.07 Mn |
| Sep 30, 2024 | -1.53 Mn |
| Sep 30, 2024 | -1.53 Mn |
| Jun 30, 2024 | 420,000.00 |
| Jun 30, 2024 | 420,000.00 |
| Mar 31, 2024 | -417,000.00 |
| Mar 31, 2024 | -417,000.00 |